Search Results for: SRC

309 interactions involving SRC - SRC proto-oncogene, non-receptor tyrosine kinase found:

Sort by: Symbol Number of Pathways Number of Drugs Number of Diseases
Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
PDE4D phosphodiesterase 4D
  • DARPP-32 events
  • G alpha (s) signalling events
  • Adenosine phosphate
  • Caffeine
  • Caffeine
  • Dyphylline
  • Iloprost
  • Amrinone
  • Roflumilast
  • Piclamilast
  • Rolipram
  • 3,5-Dimethyl-1-(3-Nitrophenyl)-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester
  • 2-[3-(2-Hydroxy-1,1-Dihydroxymethyl-Ethylamino)-Propylamino]-2-Hydroxymethyl-Propane-1,3-Diol
  • Zardaverine
  • 1-(4-Aminophenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester
  • (S)-Rolipram
  • Cilomilast
  • (R)-Rolipram
  • 3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester
  • 1-(4-Methoxyphenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester
  • Crisaborole
  • Ibudilast
  • Tetomilast
  • Exisulind
  • (4R)-4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one
  • 3,5-DIMETHYL-1-PHENYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
  • 3-isobutyl-1-methyl-7H-xanthine
  • 4-[8-(3-nitrophenyl)-1,7-naphthyridin-6-yl]benzoic acid
  • Trapidil
PELP1 proline, glutamate and leucine rich protein 1
  • Major pathway of rRNA processing in the nucleolus and cytosol
  • PTK6 Expression
PKD1 polycystin 1, transient receptor potential channel interacting
  • VxPx cargo-targeting to cilium
  • VxPx cargo-targeting to cilium
  • Polycystic kidney disease
PRKCH protein kinase C eta
  • Effects of PIP2 hydrolysis
  • G alpha (z) signalling events
PTPN18 protein tyrosine phosphatase non-receptor type 18
  • Downregulation of ERBB2 signaling
  • Interleukin-37 signaling
PTPN2 protein tyrosine phosphatase non-receptor type 2
  • Negative regulation of MET activity
  • Interleukin-37 signaling
  • Type I diabetes mellitus
RASGRF1 Ras protein specific guanine nucleotide releasing factor 1
  • Ras activation upon Ca2+ influx through NMDA receptor
  • RAF/MAP kinase cascade
RET ret proto-oncogene
  • RAF/MAP kinase cascade
  • RET signaling
  • Sorafenib
  • 1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • Vandetanib
  • Cabozantinib
  • Regorafenib
  • Ponatinib
  • Lenvatinib
  • Fostamatinib
  • Amuvatinib
  • Selpercatinib
  • Pralsetinib
  • Hirschsprung disease (HD)
  • Renal agenesis and Renal adysplasia
  • Thyroid cancer
  • Congenital central hypoventilation syndrome (CCHS)
RPS6KB2 ribosomal protein S6 kinase B2
  • AKT phosphorylates targets in the nucleus
  • Constitutive Signaling by AKT1 E17K in Cancer
SHB SH2 domain containing adaptor protein B
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
SMARCB1 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1
  • RMTs methylate histone arginines
  • RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
SMARCE1 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member 1
  • RMTs methylate histone arginines
  • RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
  • Phenethyl Isothiocyanate
SYN1 synapsin I
  • Serotonin Neurotransmitter Release Cycle
  • Dopamine Neurotransmitter Release Cycle
  • Adenosine 5'-[gamma-thio]triphosphate
  • Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Partington syndrome (PRTS); Proud syndrome (ACCAG); XMR and epilepsy (XMRE); MRXHF1; XMR OPHN1-related (MRXSO) ; XELBD; XMR, Christianson type (MRXSC); Creatine deficiency syndrome (XL-CDS); Renpenning syndrome (RENS1); Epilepsy and mental retardation limited to females (EFMR); Periventricular nodular heterotopia (PVNH); Hydrocephalus (XLH); XMR, JARID1C related (MRXSJ); Boerjeson-Forssman syndrome (BFLS); CK syndrome (CKS)
TERT telomerase reverse transcriptase
  • Telomere Extension By Telomerase
  • Formation of the beta-catenin:TCF transactivating complex
  • Zidovudine
  • Grn163l
  • Tertomotide
  • Cri du chat syndrome; Cat cry syndrome; Chromosme 5p deletion syndrome
THRB thyroid hormone receptor beta
  • Nuclear Receptor transcription pathway
  • SUMOylation of intracellular receptors
  • Liothyronine
  • Levothyroxine
  • Dextrothyroxine
  • Amiodarone
  • Liotrix
  • [3,5-Dibromo-4-(4-Hydroxy-3-Phenethylcarbamoyl-Phenoxy)-Phenyl]-Acetic Acid
  • KB-141
  • 2-[4-(4-Hydroxy-3-Isopropyl-Phenoxy)-3,5-Dimethyl-Phenyl]-2h-[1,2,4]Triazine-3,5-Dione
  • Tiratricol
  • GC-24
  • Eprotirome
  • MB07811
  • Sobetirome
  • 1-(4-HEXYLPHENYL)PROP-2-EN-1-ONE
  • Thyroid, porcine
TNFRSF11A TNF receptor superfamily member 11a
  • TNFR2 non-canonical NF-kB pathway
  • TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway
  • ENMD-1198
  • Paget's disease of bone and related disorders, including: ; Paget's disease of bone (PDB); Familial expansile osteolysis (FEO); Early-onset Paget's disease of bone (PDB2); Expansile skeletal hyperphosphatasia (ESH); Juvenile Paget's disease (JPD)
  • Osteopetrosis, including: Osteopetrosis, severe neonatal or infantile forms; Osteopetrosis, intermediate forms; Osteopetrosis with renal tubular acidosis; Osteopetrosis, late-onset form type 1; Osteopetrosis, late-onset form type 2; Osteopetrosis, osteoclast poor
TRAF1 TNF receptor associated factor 1
  • Regulation of TNFR1 signaling
  • TNFR1-induced NFkappaB signaling pathway
TRIP10 thyroid hormone receptor interactor 10
  • Rho GTPase cycle
  • Clathrin-mediated endocytosis
TXK TXK tyrosine kinase
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • Fostamatinib
  • Zanubrutinib
ARHGAP1 Rho GTPase activating protein 1
  • Rho GTPase cycle

Page 11 out of 16 pages